25-hydroxycholesterol (25hc), cryab aggregation inhibitor to amelioriate vascular stiffness
AssigneeBuck Institute for Research on Aging
InventorSimon Melov
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided herein that pertain to the discovery that the crystallin alpha B (CRYAB) gene and gene product provides an effective target for senolytic agents. In certain embodiments, methods of selectively killing one or more senescent cells in a subject in need thereof are provided where the method involves administering to the subject an effective amount of an agent that inhibits expression and/or aggregation of a CRYAB protein. In certain embodiments administration of the senolytic agent(s) describes herein decreases vascular stiffness, e.g., as measured by pulse wave velocity.
Claims38
A method of preventing or slowing an increase in vascular stiffness or of decreasing vascular stiffness in a subject, said method comprising:
- administering to said subject an effective amount of a senolytic agent.
(canceled)
-6. (canceled)
-11. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-31. (canceled)
(canceled)
(canceled)
(canceled)
-42. (canceled)
-48. (canceled)
-52. (canceled)
-60. (canceled)
Dependencies are inferred from the claim text.